Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA) Short Interest Update

Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA) was the recipient of a large increase in short interest during the month of July. As of July 31st, there was short interest totalling 115,200 shares, an increase of 852.1% from the July 15th total of 12,100 shares. Currently, 2.0% of the shares of the company are sold short. Based on an average daily trading volume, of 153,900 shares, the days-to-cover ratio is currently 0.7 days.

Hedge Funds Weigh In On Hepion Pharmaceuticals

A hedge fund recently raised its stake in Hepion Pharmaceuticals stock. Armistice Capital LLC lifted its holdings in Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA) by 5.1% in the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 418,000 shares of the company’s stock after purchasing an additional 20,393 shares during the quarter. Armistice Capital LLC owned 9.63% of Hepion Pharmaceuticals worth $1,354,000 as of its most recent filing with the SEC. 17.24% of the stock is owned by institutional investors and hedge funds.

Hepion Pharmaceuticals Stock Performance

Shares of Hepion Pharmaceuticals stock traded up $0.04 during trading on Wednesday, hitting $0.63. 77,456 shares of the stock were exchanged, compared to its average volume of 104,072. Hepion Pharmaceuticals has a 12 month low of $0.55 and a 12 month high of $7.85. The stock’s fifty day moving average is $0.95 and its 200 day moving average is $1.57. The stock has a market cap of $3.45 million, a PE ratio of -0.06 and a beta of 1.86.

Hepion Pharmaceuticals (NASDAQ:HEPA) last posted its earnings results on Tuesday, May 21st. The company reported ($0.56) EPS for the quarter.

Hepion Pharmaceuticals Company Profile

Hepion Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of drug therapy treatment for chronic liver diseases in the United States. It develops Rencofilstat, a cyclophilin inhibitor that has completed Phase 2a clinical trials to target multiple pathologic pathways involved in the progression of liver disease; and is in phase 2 clinical development for the treatment of non-alcoholic steatohepatitis (NASH), as well as preclinical studies of Rencofilstat shows reduction in liver fibrosis, liver inflammation, liver tumor burden, and titers of HBV, HCV, HDV, and HIV-1, and has demonstrated antiviral activities for hepatitis B, C, and D viruses through several mechanisms.